Interleukin-18 polymorphism as a diagnostic tumor marker for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis

Ayman Abdelghaffar Eldesoky, Nancy Abdel Fattah Ahmed*, Hosam Eldeen Zaghloul and Amr Ahmed Abdel Aziz

Abstract

Background: Egypt has the highest hepatitis C virus prevalence worldwide where about 24% of the people are estimated to carry HCV and more than 50% of blood donors have anti-HCV in some towns. The burden of hepatocellular carcinoma has been increasing in Egypt with a doubling in the incidence rate in the past 10 years. Thus, the aim of the present study was to analyze the interleukin-18 single nucleotide polymorphisms (SNPs) as a diagnostic tumor marker for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.

Results: This study included 33 hepatocellular carcinoma (HCC) complicating HCV-related cirrhosis patients, 37 cirrhotic patients without HCC (cirrhosis group), and 20 healthy individuals who were included as a control for 9 months of follow-up. SNPs of the IL-18 gene were genotyped by polymerase chain reaction. There was a statistically significant difference in the GG genotype in the HCC group in comparison with the control group (P = 0.04). There was a statistically significant difference in the G allele in the cirrhosis and HCC groups in comparison with the control group (p1 < 0.001 and p2 = 0.03, respectively). Patients with GC genotype have a risk for developing HCC by 6.33-folds more than those with GG genotype while patients with GC genotype have a risk for developing cirrhosis by 5.43-folds more than those with GG genotype, and cirrhotic patients with CC and GC genotype had a risk for developing HCC by 1.17-folds more than those with GG genotype.

Conclusion: Our findings revealed that the analysis of IL-18 single nucleotide gene polymorphism could be a valuable marker for the prediction of progress towards cirrhosis in chronic HCV patients and also to subsequent development of HCC in HCV cirrhotic patients proved by the results of both GG genotype and its G allele; also, cirrhotic patients with CC and GC genotype have a risk for developing HCC by 1.17-folds more than those with GG genotype.

Keywords: HCV, HCC, SNPs
Background

Egypt has the highest hepatitis C virus (HCV) prevalence worldwide where about 24% of the people are estimated to carry HCV [1]. Viral hepatitis was estimated to be the 7th leading cause of mortality globally. About half of this mortality is attributed to hepatitis C virus (HCV) [2]. HCC is the most common primary liver cancer with over one million new cases worldwide annually. Globally, it is the third leading cause of cancer-related deaths [3]. Alpha fetoprotein (AFP) is still the most widely used tumor biomarker currently available for detection and clinical follow-up of patients with HCC with a sensitivity of 41–65% and a specificity of 80–94%. Internationally, AFP cutoff level of 200 ng/mL is indicative of HCC [4]. Acute and chronic viral hepatitis as well as patients with cirrhosis caused by hepatitis C may be associated with slightly high AFP levels. However, this widely used marker does not yield satisfactory results in the early diagnosis of HCC limiting the universality of its application due to its low positive rate, false-positive results, and finally false-negative results [5]. As for the diagnosis of HCC, the European Association for the Study of the Liver (EASL) panel of experts and the recently updated American Association for the Study of Liver Diseases (AASLD) guidelines have proposed that imaging technique computed tomography and/or magnetic resonance imaging (CT or MRI) showing the HCC radiological hallmark, contrast uptake in the arterial phase, and washout in the venous/late phases could diagnose tumors of 1–2 cm in diameter or above [6]. IL-18 is an 18-kDa cytokine, originally known as interferon-γ (IFN-γ)-inducing factor. This cytokine is mainly produced by activated macrophages and Kupffer cells and can promote IFN-γ production [7]. Also, it participates in chronic hepatic inflammation, leading to carcinogenesis. It was reported that the serum level of IL-18 is a useful biological marker of tumor invasiveness and an independent prognostic factor for survival among patients with HCC [8]. Furthermore, the serum level of IL-18 is increased in patients with HCV-related stage IV HCC compared with patients with earlier-stage HCC [9]. IL-18 polymorphism has been proposed as a possible prognostic factor for reduced survival in patients with HCC [10]. IL-18 polymorphism has been clearly demonstrated that it contributes to tumor progression and metastasis. Although genetic predisposition is one of the factors critical for HCC progression, few studies have focused on IL-18 single nucleotide polymorphisms (SNPs) in patients with HCC. Moreover, research on the combined effect of IL-18 SNPs and HCV infection on the risk and clinico-pathologic development of HCC remains scanty [11].

Objectives

Thus, the aim of the present study was to analyze the interleukin-18 polymorphism as a diagnostic tumor marker for hepatocellular carcinoma in patients with hepatitis C-related cirrhosis.

Methods

Study design

The present study was a cross-sectional study.

Settings

The study was conducted at Mansoura Specialized Medical Hospital outpatient clinics without recruitment for 9 months of follow-up.

Participants

This study included 33 HCC complicating HCV-related cirrhosis patients (HCC group), 37 cirrhotic patients without HCC (cirrhosis group), and 20 healthy individuals who were included as a control (control group), and all of them were from Mansoura Specialized Medical Hospital outpatient clinics for 9 months. SNPs of the IL-18 gene were genotyped by polymerase chain reaction (PCR) restriction fragment-length polymorphism assays.

Variables

The inclusion criteria were as follows:

- HCC complicating HCV-related cirrhosis patients and cirrhotic patients without HCC
- Both groups are naïve
- Both gender (62.82 years mean age for the HCC group and 57.78 mean age for the cirrhosis group)
- All stages of Child-Pugh

The exclusion criteria were as follows:

- Patients with a history of cancers other than the liver
- Previous liver transplantation
- Patients co-infected with HIV or HBV
- Other organ failures (heart failure and renal failure)

Data sources/measurement

After taking a consent of the patients with ensuring the confidentiality of patients and control data, permission was taken from the head of the concerned department. All patients were subjected to history taking (name, age, sex of the patient, and smoking), previous exposure to HCV infection, history of liver disease, cirrhosis, history of medications and/toxin exposure, history of chronic diseases (DM, HTN, and other diseases), and family history of HCC. Physical examination includes a general examination for signs of liver cirrhosis (vital signs jaundice, general appearance, and spider nevi); local abdominal examination for the liver, spleen, and presence or absence of ascites; investigations—laboratory tests for
virology markers HBsAg, HCV Ab (ELISA), and HCV PCR+ve in all patients and biochemical tests for liver function tests [S. albumin, S. bilirubin, prothrombin time, INR ratio, ALT, AST], serum level of alpha fetoprotein, complete blood count, S. creatinine, and IL-18 polymorphism genotyped by polymerase chain reaction (PCR) restriction fragment-length polymorphism assays with its variants and alleles A, C, and G; and radiology, specially assessing liver (cirrhosis or HCC on top of cirrhosis): abdominal US, triphasic CT abdomen, and liver biopsy.

Bias
N/A

Study size
The study size is determined by the statistician.

Quantitative variables
N/A

Table 1 Relative risk factors for the current condition

| Variable      | Hazard ratio | 95% CI        | P value |
|---------------|--------------|---------------|---------|
| Smoking       | 1.44         | 1.02–2.11     | 0.049   |
| DM            | 1.11         | 0.96–1.29     | 0.15    |
| Male gender   | 3.96         | 2.65–5.93     | < 0.001 |
| Obesity       | 1.03         | 0.66–1.63     | 0.88    |

This table shows the increase in the relative risk of both smoking and male gender in HCC patients (P = 0.049 and P < 0.001, respectively). P value < 0.05 is significant CI confidence interval

Statistical methods
The collected data were coded and fed into the SPSS system (Statistical Package for Social Sciences) ver. 22.

Results
Participants
This study included 33 HCC complicating HCV-related cirrhosis patients (HCC group), 37 cirrhotic patients without HCC (cirrhosis group), and 20 healthy individuals who were included as a control (control group).

Descriptive data, outcome data, and main results
Descriptive data, outcome data, and main results are shown in Tables 1, 2, 3, 4, 5, 6 and 7.

Other analyses
N/A

Discussion
Key results
Our study included 33 HCC complicating HCV-related cirrhosis patients (HCC group), 37 cirrhotic patients without HCC (cirrhosis group), and 20 healthy individuals who were included as a control (control group). The HCC patients were 26 (78.8%) males and 7 (21.2%) females, and the cirrhotic patients were 14 males (37.8%) and 23 females (62.2%).

Table 2 Comparison of laboratory findings in cirrhosis and HCC groups

| Variables         | Cirrhosis group (N = 37) | HCC group (N = 33) | Test of significance |
|-------------------|--------------------------|--------------------|----------------------|
| PCR (× 10^5)      | 11.08 ± 12.48            | 4.76 ± 2.89        | P = 0.178            |
| SGPT              | 39.73 ± 29.29            | 110.85 ± 69.11     | P = 0.001*           |
| SGOT              | 43.57 ± 24.76            | 133.61 ± 140.42    | P < 0.001*           |
| Albumin           | 4.11 ± 0.61              | 2.85 ± 0.72        | P < 0.001*           |
| Total bilirubin   | 1.06 ± 0.67              | 9.68 ± 10.81       | P < 0.001*           |
| Direct bilirubin  | 0.36 ± 0.33              | 6.67 ± 7.86        | P < 0.001*           |
| INR               | 1.19 ± 0.32              | 1.46 ± 0.37        | P < 0.001*           |
| Creatinine        | 0.79 ± 0.25              | 1.61 ± 1.49        | P < 0.001*           |
| Platelets         | 145.08 ± 59.88           | 122.64 ± 66.63     | P = 0.062            |
| Hgb               | 12.91 ± 1.94             | 11.41 ± 1.88       | P = 0.002*           |
| WBCs              | 5.51 ± 1.31              | 9.67 ± 9.56        | P = 0.034*           |

This table shows significantly higher SGPT, SGOT, total bilirubin, direct bilirubin, INR, creatinine (P < 0.001 for all), and WBCs (P = 0.034) in the HCC group and significantly lower albumin and Hgb in the HCC group (P = 0.001 and P = 0.002, respectively).

*Statistically significant if P < 0.05

Table 3 Comparison of the AFP levels among the studied groups

| Variables        | Mean ± SD | Test of sig. |
|------------------|-----------|--------------|
| Control group (N = 20) | 2.87 ± 1.25 | KW = 36.485  |
| Cirrhosis group (N = 37) | 10.12 ± 15.16 | p < 0.001* |
| HCC group (N = 33)          | 345.67 ± 504.25 | p1 < 0.001* |

This table shows that AFP is highly significant in the HCC group than the cirrhosis and control groups (P < 0.001) KW Kruskal-Wallis test, P intergroup probability, p1 probability in relation to the control group, p2 probability in relation to the cirrhosis group

Table 4 ROC curve of AFP in the total studied patient

| Variables        | Cirrhotic | HCC |
|------------------|----------|-----|
| AUC (95% CI)     | 0.696 (0.56–0.83) | 0.926 (0.85–0.99) |
| Cutoff point     | ≥ 3.45   | ≥ 4.50 |
| Sensitivity (%)  | 62.2     | 84.8 |
| Specificity (%)  | 75.0     | 85.0 |
| PPV (%)          | 82.1     | 90.3 |
| NPV (%)          | 51.7     | 77.3 |
| Accuracy (%)     | 66.7     | 84.9 |

This table shows that the sensitivity and specificity of AFP in HCC patients (84.8% and 85%, respectively) and in the cirrhotic group (62.2% and 75%, respectively). The PPV and NPV in the HCC group are 90.3% and 77.3%, respectively, and 82.1% and 51.7%, respectively, in the cirrhosis group AUC area under the curve, PPV positive predictive value, NPV negative predictive value, P probability
and 23 females (62.2%) while the control group included 15 (75%) males and 5 (25%) females.

The current study is conducted aiming to analyze IL-18 single nucleotide gene polymorphism and its value in predicting HCC among HCV-related cirrhotic patients by studying 33 HCC patients with HCV-related cirrhosis, 37 cirrhotic patients without HCC, and 20 healthy individuals properly selected as a control.

Of interest, the presence of GG genotype is more in healthy control than in HCC patients ($P = 0.04$) (Table 5). A finding that could consider the presence of genotype GG of IL-18 as a good predictive marker against HCC development evidenced by lack of difference between the other genotypes (AA, AC, CC, and GC) in the studied groups and each other or the control.

Of interest, Estfanous et al. [12] reported that IL-18 polymorphism GG genotype and G allele were significantly associated with a lower risk of chronic HCV infection.

Furthermore, we find that G allele can be a protective factor against cirrhosis HCC development. This is not matching with Bouzgarrou et al. [13] who reported that IL-18 polymorphism C allele was associated with a higher risk of cirrhosis and HCC.

There were scanty studies of IL-18 single nucleotide gene polymorphism in HCV patients with or without cirrhosis. Previous studies of HCC in HBV patients confirmed abstinence of significant association of different genotypes of IL-18 in the studied patients. Dai et al. [14] reported that GG genotype carriers may increase the risk of HCC in healthy populations and the risk of LC in chronic hepatitis B carriers while Zhang and colleagues [15] reported that the AA genotype and A allele frequencies of IL-18 SNP were positively correlated with HBV-related HCC.

### Table 5

| Group | Control group (N = 20) | Cirrhosis group (N = 37) | HCC group (N = 33) | $P$ value | Within-group significance |
|-------|------------------------|--------------------------|--------------------|-----------|--------------------------|
| AA    | 4 (20%)                | 11 (29.7%)               | 9 (27.3%)          | $P = 0.727$ | p1 = 0.46, p2 = 0.56, p3 = 0.82 |
| AC    | 12 (60%)               | 19 (51.4%)               | 18 (54.5%)         | $P = 0.822$ | p1 = 0.53, p2 = 0.69, p3 = 0.79 |
| CC    | 4 (20%)                | 7 (18.9%)                | 6 (18.2%)          | $P = 0.972$ | p1 = 0.92, p2 = 0.92, p3 = 1.0 |
| CC    | 0 (0%)                 | 1 (2.7)                  | 1 (3.0)            | $P = 0.98$ | p1 = 1.0, p2 = 1.0, p3 = 1.0 |
| GC    | 1 (5%)                 | 8 (21.6%)                | 8 (24.2%)          | $P = 0.191$ | p1 = 0.10, p2 = 0.07, p3 = 0.79 |
| GG    | 19 (95%)               | 28 (75.7%)               | 24 (72.7%)         | $P = 0.03^*$ | p1 = 0.07, p2 = 0.04*, p3 = 0.78 |

This table shows that there is only a statistically significant difference in the GG genotype in the HCC group in comparison with the control group ($P = 0.04$).

$p1$ comparison of the control and cirrhosis groups, $p2$ comparison of control and HCC, $p3$ comparison of cirrhosis and HCC.

### Table 6

| IL-18 genotype allele | Group | Control group (N = 40) | Cirrhosis group (N = 74) | HCC group (N = 66) | Within-group significance |
|-----------------------|-------|------------------------|--------------------------|--------------------|--------------------------|
| A                     | 20 (50.0%) | 41 (55.4)               | 36 (54.6)               | $P = 0.58$       | p1 = 0.58, p2 = 0.65, p3 = 0.92 |
| C                     | 20 (50.0%) | 33 (44.6)               | 30 (45.4)               |                   |                          |
| G                     | 39 (97.5) | 64 (54.6)               | 56 (84.8)               | $P < 0.001^*$    | p1 = 0.001*, p2 = 0.03*, p3 = 0.78 |
| C                     | 1 (2.5)   | 10 (45.4)               | 10 (15.2)               |                   |                          |

This table shows that there is a statistically significant difference in the G allele in the cirrhosis and HCC groups in comparison with the control group ($p1 < 0.001$ and $p2 = 0.03$, respectively), and others were less significant.

$p1$ comparison of the control and cirrhosis groups, $p2$ comparison of control and HCC, $p3$ comparison of cirrhosis and HCC.
Table 7: Binary logistic regression for prediction of HCC in the studied groups

| IL-18 genotype | B     | P     | OR (95% CI) |
|----------------|-------|-------|-------------|
| CC             | B1 20.97 | P1 1.0 | OR1 undefined |
|                | B2 20.82 | P2 1.0 | OR2 undefined |
|                | B3 0.15   | P3 0.92 | OR3 1.17 (0.07–19.7) |
| GC             | B1 1.85   | P1 0.09 | OR1 6.33 (0.73–55.2) |
|                | B2 1.69   | P2 0.13 | OR2 5.43 (0.63–47.02) |
|                | B3 0.15   | P3 0.79 | OR3 1.17 (0.38–3.58) |

GG (R)

This table shows that control patients with GC genotype have a risk for developing HCC and cirrhosis by 6.33- and 5.43-folds, respectively, more than those with GG genotype while cirrhotic patients with CC and GC genotype have a risk for developing HCC by 1.17-folds more than those with GG genotype.

| B1 | B2 | B3 |
|----|----|----|
| 1.69 | 20.82 | 0.15 |

Interpretation

Our results should be interpreted with caution because of several limitations. Firstly, though we recruited 90 samples in this study, the sample size of each group was relatively small which may restrict its detailed subgroup analysis by the clinical index. Secondly, considering we just controlled four factors (D.M., gender, smoking, and obesity), other factors including environmental background, treatment protocols, and living habits may cause some bias. Thirdly, all participants were all from Mansoura Specialized Medical Hospital outpatient clinics, Egypt, which may not stand for all the Egyptian population.

Generalizability

The fundamental experiments should be further conducted to validate our results and explore the possible mechanism.

Conclusion

Analysis of IL-18 single nucleotide gene polymorphism could be a valuable marker for prediction of progress towards cirrhosis in chronic HCV patients and also to subsequent development of HCC in HCV cirrhotic patients proved by the results of both GG genotype and its G allele; also, cirrhotic patients with CC and GC genotype have a risk for developing HCC by 1.17-folds more than those with GG genotype.

Abbreviations

HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; SNPs: Single nucleotide polymorphisms; AFP: Alpha fetoprotein; CT: Computed tomography; MRI: Magnetic resonance imaging; IFN-γ: Interferon-gamma; HBsAg: Hepatitis B surface antigen; Ab: Antibody; ELISA: Enzyme-linked immunosorbent assay; PCR: Polymerase chain reaction; ALT: Alanine aminotransferase; AST: Aspartate transaminase; SPSS: Statistical Package for the Social Sciences; AUC: Area under the curve.

Acknowledgements

Thanks to every person shared in this work and the soul of Dr. Ayman A. Eldesoky.

Authors’ contributions

The authors have read and approved the manuscript. AAGD: idea of the study and data collection. NAF: manuscript review, design, editing, publishing, and final revision (CA). HEDZ: laboratory studies. AAAA: literature search, clinical follow-up, and statistics.

Funding

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study protocol was investigated and approved by the Medical Ethics Research Team, Faculty of Medicine, Mansoura University (code number MS/16.12.39). Every case, after guaranteeing privacy, has given informed written consent.

Limitations

Elastography was not done as it is very expensive for our patients. Also, the relatively small number of patients was due to the difficulty in acceptance by patients to be included in a research study in addition to the high expense of the kits.
Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Internal Medicine Department Hepatology & Gastroenterology Unit, Mansoura Specialized Medical Hospital, Mansoura University Faculty of Medicine, Mansoura, Egypt. 2Clinical Pathology Department, Mansoura University Faculty of Medicine, Mansoura, Egypt. 3Dekernes Hospital, Dakahlia, Egypt.

Received: 29 July 2020 Accepted: 26 October 2020
Published online: 05 November 2020

References
1. Omar A, Abou-Alfa GK, Khairt A et al (2013) Risk factors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol 2(4):43
2. Kouyoujian SP, Chemaitelly H, Abu-Raddad LI (2018) Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep 8(1):1661
3. Murata S, Mine T, Ueda T et al (2013) Transcatheter arterial chemoembolization based on hepatic hemodynamics for hepatocellular carcinoma. Sci World J 479805:1–8
4. Behne T, Copur MS (2012) Biomarkers for hepatocellular carcinoma. Int J Hepatol 2012:859076
5. Zhao YJ, Qiang JU, Guan-Cheng LI (2013) Tumor markers for hepatocellular carcinoma. Mol Clin Oncol 1(4):593–598
6. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020
7. Yue M, Wang JJ, Tang SD et al (2013) Association of interleukin-18 gene polymorphisms with the outcomes of hepatitis C virus infection in high-risk Chinese Han population. Immunol Lett 154:54–60
8. Tangijvanich P, Thong-Ngam D, Mahachai V et al (2007) Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 13:4345–4349
9. Shiraiki T, Takayama E, Magari H et al (2011) Altered cytokine levels and increased CD4+CD57+ T cells in the peripheral blood of hepatitis C virus-related hepatocellular carcinoma patients. Oncol Rep 26:201–208
10. Chen TP, Lee HL, Huang YH et al (2016) Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol 80:607–614
11. Estfanous SZK, Ali SA, Selim M, Soror SHA (2019) Inflammasome genes’ polymorphisms in Egyptian chronic hepatitis C patients: influence on vulnerability to infection and response to treatment. Mediators Inflamm 2019:3273645
12. Lau H-K, Hsieh M-J, Yang S-F et al (2016) Association between interleukin-18 polymorphisms and hepatocellular carcinoma occurrence and clinical progression. Int J Med Sci 13(7):556–561
13. Bao J, Lu Y, Deng Y et al (2015) Association between IL-18 polymorphisms, serum levels and HBV-related hepatocellular carcinoma in a Chinese population: a retrospective case-control study. Cancer Cell Int 15:72
14. Bakr NM, Awad A, Moustafa E (2018) Association of genetic variants in the interleukin-18 gene promoter with risk of hepatocellular carcinoma and metastasis in patients with hepatitis C virus infection. IUBMB Life 70(2):165–174

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.